Discovery of a pyrrole-pyridinimidazole derivative as novel SIRT6 inhibitor for sensitizing pancreatic cancer to gemcitabine
Pancreatic cancer is a highly aggressive cancer, and is primarily treated with gemcitabine, with increasing resistance. SIRT6 as a member of sirtuin family plays important roles in lifespan and diverse diseases, such as cancer, diabetes, inflammation and neurodegenerative diseases. Considering the r...
Saved in:
Published in | Cell death & disease Vol. 14; no. 8; p. 499 |
---|---|
Main Authors | , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
England
Springer Nature B.V
04.08.2023
Nature Publishing Group UK Nature Publishing Group |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Pancreatic cancer is a highly aggressive cancer, and is primarily treated with gemcitabine, with increasing resistance. SIRT6 as a member of sirtuin family plays important roles in lifespan and diverse diseases, such as cancer, diabetes, inflammation and neurodegenerative diseases. Considering the role of SIRT6 in the cytoprotective effect, it might be a potential anticancer drug target, and is associated with resistance to anticancer therapy. However, very few SIRT6 inhibitors have been reported. Here, we reported the discovery of a pyrrole-pyridinimidazole derivative, 8a, as a new non-competitive SIRT6 inhibitor, and studied its roles and mechanisms in the antitumor activity and sensitization of pancreatic cancer to gemcitabine. Firstly, we found a potent SIRT6 inhibitor compound 8a by virtual screening and identified by molecular and cellular SIRT6 activity assays. 8a could effectively inhibit SIRT6 deacetylation activity with IC
values of 7.46 ± 0.79 μM in FLUOR DE LYS assay, and 8a significantly increased the acetylation levels of H3 in cells. Then, we found that 8a could inhibit the cell proliferation and induce cell apoptosis in pancreatic cancer cells. We further demonstrate that 8a sensitize pancreatic cancer cells to gemcitabine via reversing the activation of PI3K/AKT/mTOR and ERK signaling pathways induced by gemcitabine and blocking the DNA damage repair pathway. Moreover, combination of 8a and gemcitabine induces cooperative antitumor activity in pancreatic cancer xenograft model in vivo. Overall, we demonstrate that 8a, a novel SIRT6 inhibitor, could be a promising potential drug candidate for pancreatic cancer treatment. |
---|---|
AbstractList | Pancreatic cancer is a highly aggressive cancer, and is primarily treated with gemcitabine, with increasing resistance. SIRT6 as a member of sirtuin family plays important roles in lifespan and diverse diseases, such as cancer, diabetes, inflammation and neurodegenerative diseases. Considering the role of SIRT6 in the cytoprotective effect, it might be a potential anticancer drug target, and is associated with resistance to anticancer therapy. However, very few SIRT6 inhibitors have been reported. Here, we reported the discovery of a pyrrole-pyridinimidazole derivative, 8a, as a new non-competitive SIRT6 inhibitor, and studied its roles and mechanisms in the antitumor activity and sensitization of pancreatic cancer to gemcitabine. Firstly, we found a potent SIRT6 inhibitor compound 8a by virtual screening and identified by molecular and cellular SIRT6 activity assays. 8a could effectively inhibit SIRT6 deacetylation activity with IC
50
values of 7.46 ± 0.79 μM in FLUOR DE LYS assay, and 8a significantly increased the acetylation levels of H3 in cells. Then, we found that 8a could inhibit the cell proliferation and induce cell apoptosis in pancreatic cancer cells. We further demonstrate that 8a sensitize pancreatic cancer cells to gemcitabine via reversing the activation of PI3K/AKT/mTOR and ERK signaling pathways induced by gemcitabine and blocking the DNA damage repair pathway. Moreover, combination of 8a and gemcitabine induces cooperative antitumor activity in pancreatic cancer xenograft model in vivo. Overall, we demonstrate that 8a, a novel SIRT6 inhibitor, could be a promising potential drug candidate for pancreatic cancer treatment. Abstract Pancreatic cancer is a highly aggressive cancer, and is primarily treated with gemcitabine, with increasing resistance. SIRT6 as a member of sirtuin family plays important roles in lifespan and diverse diseases, such as cancer, diabetes, inflammation and neurodegenerative diseases. Considering the role of SIRT6 in the cytoprotective effect, it might be a potential anticancer drug target, and is associated with resistance to anticancer therapy. However, very few SIRT6 inhibitors have been reported. Here, we reported the discovery of a pyrrole-pyridinimidazole derivative, 8a, as a new non-competitive SIRT6 inhibitor, and studied its roles and mechanisms in the antitumor activity and sensitization of pancreatic cancer to gemcitabine. Firstly, we found a potent SIRT6 inhibitor compound 8a by virtual screening and identified by molecular and cellular SIRT6 activity assays. 8a could effectively inhibit SIRT6 deacetylation activity with IC50 values of 7.46 ± 0.79 μM in FLUOR DE LYS assay, and 8a significantly increased the acetylation levels of H3 in cells. Then, we found that 8a could inhibit the cell proliferation and induce cell apoptosis in pancreatic cancer cells. We further demonstrate that 8a sensitize pancreatic cancer cells to gemcitabine via reversing the activation of PI3K/AKT/mTOR and ERK signaling pathways induced by gemcitabine and blocking the DNA damage repair pathway. Moreover, combination of 8a and gemcitabine induces cooperative antitumor activity in pancreatic cancer xenograft model in vivo. Overall, we demonstrate that 8a, a novel SIRT6 inhibitor, could be a promising potential drug candidate for pancreatic cancer treatment. Pancreatic cancer is a highly aggressive cancer, and is primarily treated with gemcitabine, with increasing resistance. SIRT6 as a member of sirtuin family plays important roles in lifespan and diverse diseases, such as cancer, diabetes, inflammation and neurodegenerative diseases. Considering the role of SIRT6 in the cytoprotective effect, it might be a potential anticancer drug target, and is associated with resistance to anticancer therapy. However, very few SIRT6 inhibitors have been reported. Here, we reported the discovery of a pyrrole-pyridinimidazole derivative, 8a, as a new non-competitive SIRT6 inhibitor, and studied its roles and mechanisms in the antitumor activity and sensitization of pancreatic cancer to gemcitabine. Firstly, we found a potent SIRT6 inhibitor compound 8a by virtual screening and identified by molecular and cellular SIRT6 activity assays. 8a could effectively inhibit SIRT6 deacetylation activity with IC values of 7.46 ± 0.79 μM in FLUOR DE LYS assay, and 8a significantly increased the acetylation levels of H3 in cells. Then, we found that 8a could inhibit the cell proliferation and induce cell apoptosis in pancreatic cancer cells. We further demonstrate that 8a sensitize pancreatic cancer cells to gemcitabine via reversing the activation of PI3K/AKT/mTOR and ERK signaling pathways induced by gemcitabine and blocking the DNA damage repair pathway. Moreover, combination of 8a and gemcitabine induces cooperative antitumor activity in pancreatic cancer xenograft model in vivo. Overall, we demonstrate that 8a, a novel SIRT6 inhibitor, could be a promising potential drug candidate for pancreatic cancer treatment. Abstract Pancreatic cancer is a highly aggressive cancer, and is primarily treated with gemcitabine, with increasing resistance. SIRT6 as a member of sirtuin family plays important roles in lifespan and diverse diseases, such as cancer, diabetes, inflammation and neurodegenerative diseases. Considering the role of SIRT6 in the cytoprotective effect, it might be a potential anticancer drug target, and is associated with resistance to anticancer therapy. However, very few SIRT6 inhibitors have been reported. Here, we reported the discovery of a pyrrole-pyridinimidazole derivative, 8a, as a new non-competitive SIRT6 inhibitor, and studied its roles and mechanisms in the antitumor activity and sensitization of pancreatic cancer to gemcitabine. Firstly, we found a potent SIRT6 inhibitor compound 8a by virtual screening and identified by molecular and cellular SIRT6 activity assays. 8a could effectively inhibit SIRT6 deacetylation activity with IC 50 values of 7.46 ± 0.79 μM in FLUOR DE LYS assay, and 8a significantly increased the acetylation levels of H3 in cells. Then, we found that 8a could inhibit the cell proliferation and induce cell apoptosis in pancreatic cancer cells. We further demonstrate that 8a sensitize pancreatic cancer cells to gemcitabine via reversing the activation of PI3K/AKT/mTOR and ERK signaling pathways induced by gemcitabine and blocking the DNA damage repair pathway. Moreover, combination of 8a and gemcitabine induces cooperative antitumor activity in pancreatic cancer xenograft model in vivo. Overall, we demonstrate that 8a, a novel SIRT6 inhibitor, could be a promising potential drug candidate for pancreatic cancer treatment. Pancreatic cancer is a highly aggressive cancer, and is primarily treated with gemcitabine, with increasing resistance. SIRT6 as a member of sirtuin family plays important roles in lifespan and diverse diseases, such as cancer, diabetes, inflammation and neurodegenerative diseases. Considering the role of SIRT6 in the cytoprotective effect, it might be a potential anticancer drug target, and is associated with resistance to anticancer therapy. However, very few SIRT6 inhibitors have been reported. Here, we reported the discovery of a pyrrole-pyridinimidazole derivative, 8a, as a new non-competitive SIRT6 inhibitor, and studied its roles and mechanisms in the antitumor activity and sensitization of pancreatic cancer to gemcitabine. Firstly, we found a potent SIRT6 inhibitor compound 8a by virtual screening and identified by molecular and cellular SIRT6 activity assays. 8a could effectively inhibit SIRT6 deacetylation activity with IC50 values of 7.46 ± 0.79 μM in FLUOR DE LYS assay, and 8a significantly increased the acetylation levels of H3 in cells. Then, we found that 8a could inhibit the cell proliferation and induce cell apoptosis in pancreatic cancer cells. We further demonstrate that 8a sensitize pancreatic cancer cells to gemcitabine via reversing the activation of PI3K/AKT/mTOR and ERK signaling pathways induced by gemcitabine and blocking the DNA damage repair pathway. Moreover, combination of 8a and gemcitabine induces cooperative antitumor activity in pancreatic cancer xenograft model in vivo. Overall, we demonstrate that 8a, a novel SIRT6 inhibitor, could be a promising potential drug candidate for pancreatic cancer treatment. |
ArticleNumber | 499 |
Author | Song, Nannan Yu, Wengong Zhang, Siqi Wang, Yanqing Wang, Xuekai Chong, Daochen Lu, Zhongxia Jiang, Tao Wang, Jennifer Yiyang Guan, Xian Yu, Rilei Gu, Yuchao |
Author_xml | – sequence: 1 givenname: Nannan orcidid: 0009-0005-7979-5081 surname: Song fullname: Song, Nannan organization: Key Laboratory of Marine Drugs, Ministry of Education, School of Medicine and Pharmacy, Ocean University of China, Qingdao, 266003, China – sequence: 2 givenname: Xian surname: Guan fullname: Guan, Xian organization: Key Laboratory of Marine Drugs, Ministry of Education, School of Medicine and Pharmacy, Ocean University of China, Qingdao, 266003, China – sequence: 3 givenname: Siqi surname: Zhang fullname: Zhang, Siqi organization: Key Laboratory of Marine Drugs, Ministry of Education, School of Medicine and Pharmacy, Ocean University of China, Qingdao, 266003, China – sequence: 4 givenname: Yanqing surname: Wang fullname: Wang, Yanqing organization: Key Laboratory of Marine Drugs, Ministry of Education, School of Medicine and Pharmacy, Ocean University of China, Qingdao, 266003, China – sequence: 5 givenname: Xuekai surname: Wang fullname: Wang, Xuekai organization: Key Laboratory of Marine Drugs, Ministry of Education, School of Medicine and Pharmacy, Ocean University of China, Qingdao, 266003, China – sequence: 6 givenname: Zhongxia surname: Lu fullname: Lu, Zhongxia organization: Key Laboratory of Marine Drugs, Ministry of Education, School of Medicine and Pharmacy, Ocean University of China, Qingdao, 266003, China – sequence: 7 givenname: Daochen surname: Chong fullname: Chong, Daochen organization: Department of Pathology, 971 Hospital of PLA Navy, Qingdao, 266071, China – sequence: 8 givenname: Jennifer Yiyang orcidid: 0000-0002-1697-8615 surname: Wang fullname: Wang, Jennifer Yiyang organization: Key Laboratory of Marine Drugs, Ministry of Education, School of Medicine and Pharmacy, Ocean University of China, Qingdao, 266003, China – sequence: 9 givenname: Rilei surname: Yu fullname: Yu, Rilei organization: Laboratory for Marine Drugs and Bioproducts of Qingdao National Laboratory for Marine Science and Technology, Qingdao, 266237, China – sequence: 10 givenname: Wengong orcidid: 0009-0009-5634-931X surname: Yu fullname: Yu, Wengong email: yuwg66@ouc.edu.cn, yuwg66@ouc.edu.cn organization: Laboratory for Marine Drugs and Bioproducts of Qingdao National Laboratory for Marine Science and Technology, Qingdao, 266237, China. yuwg66@ouc.edu.cn – sequence: 11 givenname: Tao orcidid: 0000-0002-6590-5041 surname: Jiang fullname: Jiang, Tao email: jiangtao@ouc.edu.cn, jiangtao@ouc.edu.cn organization: Laboratory for Marine Drugs and Bioproducts of Qingdao National Laboratory for Marine Science and Technology, Qingdao, 266237, China. jiangtao@ouc.edu.cn – sequence: 12 givenname: Yuchao orcidid: 0000-0002-8723-3899 surname: Gu fullname: Gu, Yuchao email: guych@ouc.edu.cn, guych@ouc.edu.cn organization: Laboratory for Marine Drugs and Bioproducts of Qingdao National Laboratory for Marine Science and Technology, Qingdao, 266237, China. guych@ouc.edu.cn |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/37542062$$D View this record in MEDLINE/PubMed |
BookMark | eNpdUltrVDEQPkjF1to_4IMEfPHlaG4nlyeR1stCQdD6HHJO5myznE3W5OxCiz_e2W4trRnCDJNvvkwm38vmKOUETfOa0feMCvOhSiaZbSkXLVWUmZY9a044layVxtijR_Fxc1briuISgvJOvWiOhe4kp4qfNH8uYh3yDsoNySPxZHNTSp6gRR9DTHEdg7_FBAlQ4s7PcQfEV5KwZCI_Fz-uFInpOvZxzoWMuCukGud4G9OSbHwaCmDRQAYMoZA5kyWshzj7PiZ41Twf_VTh7N6fNr--fL46_9Zefv-6OP902Q7S6rkVo1I8dKHXsmdKCcZtr6wZOuONDlJq2yklNUMbega0kxrBwEDjdBjaabM48IbsV25T4tqXG5d9dHeJXJbOF-xyAmeF6ZgarZfWyIBBMNyAYUF2ATMKuT4euDbbfg1hgDQXPz0hfXqS4rVb5p1jVFLRaYkM7-4ZSv69hTq7Nf4BTJNPkLfVcbzGCk6pRejb_6CrvC0JZ7VHdVZrozii-AE1lFxrgfGhG0bdXizuIBaH43B3YnH7mbx5_I6Hkn_SEH8BBi68BQ |
CitedBy_id | crossref_primary_10_3389_fphar_2023_1335305 crossref_primary_10_3390_molecules29051185 crossref_primary_10_1016_j_ijbiomac_2024_130055 crossref_primary_10_3390_md21100517 |
Cites_doi | 10.1101/gad.13.22.2905 10.1016/j.tem.2016.10.002 10.3390/md17090500 10.18388/pb.2020_319 10.1039/C2NP20112G 10.1002/med.21753 10.1038/s41589-018-0150-0 10.2174/156802610790232251 10.1038/nature08197 10.1097/CAD.0000000000000165 10.1074/jbc.M113.484576 10.1001/jama.2021.13027 10.1016/j.biotechadv.2013.02.006 10.1016/j.phymed.2018.11.025 10.1016/j.cell.2008.10.052 10.1530/JOE-16-0317 10.1186/s13046-018-0772-9 10.1016/j.bmc.2021.116058 10.1016/j.bbrc.2017.01.146 10.1016/j.cell.2005.11.044 10.3390/md11072510 10.1021/jm400204k 10.1007/s00125-017-4542-6 10.1186/s13046-020-01623-w 10.1111/cas.14648 10.3389/fonc.2022.861334 10.1038/s41374-021-00715-1 10.1186/s13046-020-01759-9 10.1016/j.apsb.2021.06.015 10.1021/jm500487d 10.1038/nprot.2014.138 10.1016/j.ejmech.2015.08.024 10.1667/RR14443.1 10.1016/S0092-8674(00)81482-8 10.1007/s00125-015-3778-2 10.2174/15680266113136660213 10.3322/caac.21660 10.18632/aging.100011 10.1002/jso.23975 10.1126/science.1202723 10.1091/mbc.e05-01-0033 10.1177/17562848211014818 10.1016/j.ejphar.2014.07.041 10.1074/jbc.273.10.5858 10.2174/0929867324666170206142658 10.1016/j.critrevonc.2017.03.026 10.1016/j.bmc.2017.09.023 10.1158/1535-7163.MCT-09-1012 |
ContentType | Journal Article |
Copyright | 2023. The Author(s). The Author(s) 2023. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. The Author(s) 2023 |
Copyright_xml | – notice: 2023. The Author(s). – notice: The Author(s) 2023. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: The Author(s) 2023 |
DBID | CGR CUY CVF ECM EIF NPM AAYXX CITATION 3V. 7X7 7XB 88A 88I 8FE 8FH 8FI 8FJ 8FK ABUWG AFKRA AZQEC BBNVY BENPR BHPHI CCPQU DWQXO FYUFA GHDGH GNUQQ HCIFZ K9. LK8 M0S M2P M7P PIMPY PQEST PQQKQ PQUKI Q9U 7X8 5PM DOA |
DOI | 10.1038/s41419-023-06018-1 |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef ProQuest Central (Corporate) ProQuest_Health & Medical Collection ProQuest Central (purchase pre-March 2016) Biology Database (Alumni Edition) Science Database (Alumni Edition) ProQuest SciTech Collection ProQuest Natural Science Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central ProQuest Central Essentials Biological Science Collection AUTh Library subscriptions: ProQuest Central ProQuest Natural Science Collection ProQuest One Community College ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student SciTech Premium Collection ProQuest Health & Medical Complete (Alumni) ProQuest Biological Science Collection Health & Medical Collection (Alumni Edition) Science Journals (ProQuest Database) Biological Science Database ProQuest - Publicly Available Content Database ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central Basic MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef Publicly Available Content Database ProQuest Central Student ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College ProQuest Natural Science Collection ProQuest Biology Journals (Alumni Edition) ProQuest Central Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Natural Science Collection ProQuest Central Korea Biological Science Collection ProQuest Science Journals (Alumni Edition) ProQuest Biological Science Collection ProQuest Central Basic ProQuest Science Journals ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) Biological Science Database ProQuest SciTech Collection ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest One Academic UKI Edition ProQuest One Academic ProQuest Central (Alumni) MEDLINE - Academic |
DatabaseTitleList | MEDLINE CrossRef Publicly Available Content Database |
Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 4 dbid: BENPR name: AUTh Library subscriptions: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Biology |
EISSN | 2041-4889 |
EndPage | 499 |
ExternalDocumentID | oai_doaj_org_article_938516f9a4984d6f9d828e81d45d9846 10_1038_s41419_023_06018_1 37542062 |
Genre | Research Support, Non-U.S. Gov't Journal Article |
GrantInformation_xml | – fundername: ; |
GroupedDBID | --- 0R~ 3V. 53G 5VS 70F 7X7 88A 88I 8FE 8FH 8FI 8FJ AAADF AAJSJ ABUWG ACGFS ACSMW ADBBV AENEX AFGXO AFKRA AJTQC ALIPV ALMA_UNASSIGNED_HOLDINGS AOIJS AZQEC BAWUL BBNVY BCNDV BENPR BHPHI BPHCQ BVXVI CCPQU CGR CUY CVF DIK DWQXO E3Z EBS ECM EIF EMOBN FRP FYUFA GNUQQ GROUPED_DOAJ HCIFZ HMCUK HYE HZ~ KQ8 LK8 M0L M2P M48 M7P M~E NAO NPM O5R O5S O9- OK1 PIMPY PQQKQ PROAC RIG RNT RPM SNYQT TR2 UKHRP W2D AAYXX C6C CITATION EBLON 7XB 8FK K9. PQEST PQUKI Q9U 7X8 5PM |
ID | FETCH-LOGICAL-c497t-3f662d5db74b1663129b698c58a87d4479566471717cb1e05475dbe1e70231313 |
IEDL.DBID | RPM |
ISSN | 2041-4889 |
IngestDate | Thu Jul 04 21:11:15 EDT 2024 Tue Sep 17 21:31:16 EDT 2024 Fri Aug 16 04:12:30 EDT 2024 Fri Sep 13 03:13:29 EDT 2024 Fri Aug 23 01:19:26 EDT 2024 Sun Jun 23 00:34:07 EDT 2024 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 8 |
Language | English |
License | 2023. The Author(s). Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c497t-3f662d5db74b1663129b698c58a87d4479566471717cb1e05475dbe1e70231313 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ORCID | 0009-0005-7979-5081 0000-0002-6590-5041 0000-0002-1697-8615 0009-0009-5634-931X 0000-0002-8723-3899 |
OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10403574/ |
PMID | 37542062 |
PQID | 2845977862 |
PQPubID | 2041963 |
PageCount | 1 |
ParticipantIDs | doaj_primary_oai_doaj_org_article_938516f9a4984d6f9d828e81d45d9846 pubmedcentral_primary_oai_pubmedcentral_nih_gov_10403574 proquest_miscellaneous_2846932009 proquest_journals_2845977862 crossref_primary_10_1038_s41419_023_06018_1 pubmed_primary_37542062 |
PublicationCentury | 2000 |
PublicationDate | 2023-08-04 |
PublicationDateYYYYMMDD | 2023-08-04 |
PublicationDate_xml | – month: 08 year: 2023 text: 2023-08-04 day: 04 |
PublicationDecade | 2020 |
PublicationPlace | England |
PublicationPlace_xml | – name: England – name: London |
PublicationTitle | Cell death & disease |
PublicationTitleAlternate | Cell Death Dis |
PublicationYear | 2023 |
Publisher | Springer Nature B.V Nature Publishing Group UK Nature Publishing Group |
Publisher_xml | – name: Springer Nature B.V – name: Nature Publishing Group UK – name: Nature Publishing Group |
References | G Sociali (6018_CR17) 2015; 102 SR Datta (6018_CR30) 1999; 13 MW Ha (6018_CR23) 2019; 17 SE Lee (6018_CR38) 1998; 94 P Damonte (6018_CR15) 2017; 25 J Chi (6018_CR13) 2021; 14 JW Blunt (6018_CR21) 2013; 30 E Michishita (6018_CR28) 2005; 16 C Grasso (6018_CR3) 2017; 114 C Zhang (6018_CR32) 2019; 20 Y Li (6018_CR11) 2022; 12 T Finkel (6018_CR4) 2009; 460 Z Mao (6018_CR10) 2011; 332 TL Kawahara (6018_CR27) 2009; 136 S Ebrahimi (6018_CR50) 2017; 24 S Vinothkumar (6018_CR19) 2013; 31 WY Lu (6018_CR20) 2021; 35 X Xiong (6018_CR7) 2016; 231 Z Huang (6018_CR25) 2018; 14 H Yoneyama (6018_CR49) 2015; 26 MM Im (6018_CR37) 2016; 186 C Bian (6018_CR44) 2022; 102 J Ma (6018_CR39) 2017; 484 RA McCord (6018_CR9) 2009; 1 K Qin (6018_CR6) 2018; 61 L Tasselli (6018_CR42) 2017; 28 EP Rogakou (6018_CR41) 1998; 273 Q Zhang (6018_CR18) 2022; 12 W Park (6018_CR29) 2021; 326 M Kciuk (6018_CR40) 2020; 66 R Mostoslavsky (6018_CR8) 2006; 124 L Ba (6018_CR31) 2019; 58 H Sung (6018_CR1) 2021; 71 Z Zhang (6018_CR14) 2020; 39 AM Mayer (6018_CR22) 2013; 11 JS Disch (6018_CR24) 2013; 56 TT Talele (6018_CR47) 2010; 10 Z Wang (6018_CR36) 2020; 19 G Liu (6018_CR5) 2021; 41 MD Parenti (6018_CR16) 2014; 57 J Yang (6018_CR33) 2020; 39 H Hirai (6018_CR34) 2010; 9 HJ Park (6018_CR12) 2018; 37 S Arora (6018_CR35) 2013; 288 X Xiong (6018_CR43) 2016; 59 L de Sousa Cavalcante (6018_CR2) 2014; 741 Y Azuma (6018_CR46) 2015; 112 R Jafari (6018_CR26) 2014; 9 L Song (6018_CR48) 2020; 111 JP Etchegaray (6018_CR45) 2013; 13 |
References_xml | – volume: 13 start-page: 2905 year: 1999 ident: 6018_CR30 publication-title: Genes Dev doi: 10.1101/gad.13.22.2905 contributor: fullname: SR Datta – volume: 28 start-page: 168 year: 2017 ident: 6018_CR42 publication-title: Trends Endocrinol Metab doi: 10.1016/j.tem.2016.10.002 contributor: fullname: L Tasselli – volume: 17 start-page: 500 year: 2019 ident: 6018_CR23 publication-title: Mar Drugs doi: 10.3390/md17090500 contributor: fullname: MW Ha – volume: 66 start-page: 160 year: 2020 ident: 6018_CR40 publication-title: Postepy Biochem doi: 10.18388/pb.2020_319 contributor: fullname: M Kciuk – volume: 30 start-page: 237 year: 2013 ident: 6018_CR21 publication-title: Nat Prod Rep doi: 10.1039/C2NP20112G contributor: fullname: JW Blunt – volume: 41 start-page: 1089 year: 2021 ident: 6018_CR5 publication-title: Med Res Rev doi: 10.1002/med.21753 contributor: fullname: G Liu – volume: 14 start-page: 1118 year: 2018 ident: 6018_CR25 publication-title: Nat Chem Biol doi: 10.1038/s41589-018-0150-0 contributor: fullname: Z Huang – volume: 10 start-page: 127 year: 2010 ident: 6018_CR47 publication-title: Curr Top Med Chem doi: 10.2174/156802610790232251 contributor: fullname: TT Talele – volume: 460 start-page: 587 year: 2009 ident: 6018_CR4 publication-title: Nature. doi: 10.1038/nature08197 contributor: fullname: T Finkel – volume: 26 start-page: 90 year: 2015 ident: 6018_CR49 publication-title: Anticancer Drugs doi: 10.1097/CAD.0000000000000165 contributor: fullname: H Yoneyama – volume: 288 start-page: 21197 year: 2013 ident: 6018_CR35 publication-title: J Biol Chem doi: 10.1074/jbc.M113.484576 contributor: fullname: S Arora – volume: 326 start-page: 851 year: 2021 ident: 6018_CR29 publication-title: JAMA. doi: 10.1001/jama.2021.13027 contributor: fullname: W Park – volume: 31 start-page: 1826 year: 2013 ident: 6018_CR19 publication-title: Biotechnol Adv doi: 10.1016/j.biotechadv.2013.02.006 contributor: fullname: S Vinothkumar – volume: 58 start-page: 152765 year: 2019 ident: 6018_CR31 publication-title: Phytomedicine. doi: 10.1016/j.phymed.2018.11.025 contributor: fullname: L Ba – volume: 136 start-page: 62 year: 2009 ident: 6018_CR27 publication-title: Cell. doi: 10.1016/j.cell.2008.10.052 contributor: fullname: TL Kawahara – volume: 231 start-page: 159 year: 2016 ident: 6018_CR7 publication-title: J Endocrinol doi: 10.1530/JOE-16-0317 contributor: fullname: X Xiong – volume: 37 start-page: 107 year: 2018 ident: 6018_CR12 publication-title: J Exp Clin Cancer Res doi: 10.1186/s13046-018-0772-9 contributor: fullname: HJ Park – volume: 35 start-page: 116058 year: 2021 ident: 6018_CR20 publication-title: Bioorg Med Chem doi: 10.1016/j.bmc.2021.116058 contributor: fullname: WY Lu – volume: 484 start-page: 746 year: 2017 ident: 6018_CR39 publication-title: Biochem Biophys Res Commun doi: 10.1016/j.bbrc.2017.01.146 contributor: fullname: J Ma – volume: 124 start-page: 315 year: 2006 ident: 6018_CR8 publication-title: Cell. doi: 10.1016/j.cell.2005.11.044 contributor: fullname: R Mostoslavsky – volume: 11 start-page: 2510 year: 2013 ident: 6018_CR22 publication-title: Mar Drugs doi: 10.3390/md11072510 contributor: fullname: AM Mayer – volume: 56 start-page: 3666 year: 2013 ident: 6018_CR24 publication-title: J Med Chem doi: 10.1021/jm400204k contributor: fullname: JS Disch – volume: 19 start-page: 1999 year: 2020 ident: 6018_CR36 publication-title: Oncol Lett contributor: fullname: Z Wang – volume: 61 start-page: 906 year: 2018 ident: 6018_CR6 publication-title: Diabetologia. doi: 10.1007/s00125-017-4542-6 contributor: fullname: K Qin – volume: 39 start-page: 142 year: 2020 ident: 6018_CR33 publication-title: J Exp Clin Cancer Res doi: 10.1186/s13046-020-01623-w contributor: fullname: J Yang – volume: 111 start-page: 4242 year: 2020 ident: 6018_CR48 publication-title: Cancer Sci doi: 10.1111/cas.14648 contributor: fullname: L Song – volume: 12 start-page: 861334 year: 2022 ident: 6018_CR11 publication-title: Front Oncol doi: 10.3389/fonc.2022.861334 contributor: fullname: Y Li – volume: 102 start-page: 474 year: 2022 ident: 6018_CR44 publication-title: Lab Invest doi: 10.1038/s41374-021-00715-1 contributor: fullname: C Bian – volume: 39 start-page: 247 year: 2020 ident: 6018_CR14 publication-title: J Exp Clin Cancer Res doi: 10.1186/s13046-020-01759-9 contributor: fullname: Z Zhang – volume: 12 start-page: 876 year: 2022 ident: 6018_CR18 publication-title: Acta Pharm Sin B. doi: 10.1016/j.apsb.2021.06.015 contributor: fullname: Q Zhang – volume: 57 start-page: 4796 year: 2014 ident: 6018_CR16 publication-title: J Med Chem doi: 10.1021/jm500487d contributor: fullname: MD Parenti – volume: 9 start-page: 2100 year: 2014 ident: 6018_CR26 publication-title: Nat Protoc doi: 10.1038/nprot.2014.138 contributor: fullname: R Jafari – volume: 102 start-page: 530 year: 2015 ident: 6018_CR17 publication-title: Eur J Med Chem doi: 10.1016/j.ejmech.2015.08.024 contributor: fullname: G Sociali – volume: 20 start-page: 1575 year: 2019 ident: 6018_CR32 publication-title: Mol Med Rep contributor: fullname: C Zhang – volume: 186 start-page: 466 year: 2016 ident: 6018_CR37 publication-title: Radiat Res doi: 10.1667/RR14443.1 contributor: fullname: MM Im – volume: 94 start-page: 399 year: 1998 ident: 6018_CR38 publication-title: Cell. doi: 10.1016/S0092-8674(00)81482-8 contributor: fullname: SE Lee – volume: 59 start-page: 151 year: 2016 ident: 6018_CR43 publication-title: Diabetologia. doi: 10.1007/s00125-015-3778-2 contributor: fullname: X Xiong – volume: 13 start-page: 2991 year: 2013 ident: 6018_CR45 publication-title: Curr Top Med Chem doi: 10.2174/15680266113136660213 contributor: fullname: JP Etchegaray – volume: 71 start-page: 209 year: 2021 ident: 6018_CR1 publication-title: CA Cancer J Clin doi: 10.3322/caac.21660 contributor: fullname: H Sung – volume: 1 start-page: 109 year: 2009 ident: 6018_CR9 publication-title: Aging doi: 10.18632/aging.100011 contributor: fullname: RA McCord – volume: 112 start-page: 231 year: 2015 ident: 6018_CR46 publication-title: J Surg Oncol doi: 10.1002/jso.23975 contributor: fullname: Y Azuma – volume: 332 start-page: 1443 year: 2011 ident: 6018_CR10 publication-title: Science. doi: 10.1126/science.1202723 contributor: fullname: Z Mao – volume: 16 start-page: 4623 year: 2005 ident: 6018_CR28 publication-title: Mol Biol Cell doi: 10.1091/mbc.e05-01-0033 contributor: fullname: E Michishita – volume: 14 start-page: 175628482110148 year: 2021 ident: 6018_CR13 publication-title: Ther Adv Gastroenterol doi: 10.1177/17562848211014818 contributor: fullname: J Chi – volume: 741 start-page: 8 year: 2014 ident: 6018_CR2 publication-title: Eur J Pharmacol doi: 10.1016/j.ejphar.2014.07.041 contributor: fullname: L de Sousa Cavalcante – volume: 273 start-page: 5858 year: 1998 ident: 6018_CR41 publication-title: J Biol Chem doi: 10.1074/jbc.273.10.5858 contributor: fullname: EP Rogakou – volume: 24 start-page: 1321 year: 2017 ident: 6018_CR50 publication-title: Curr Med Chem doi: 10.2174/0929867324666170206142658 contributor: fullname: S Ebrahimi – volume: 114 start-page: 139 year: 2017 ident: 6018_CR3 publication-title: Crit Rev Oncol Hematol doi: 10.1016/j.critrevonc.2017.03.026 contributor: fullname: C Grasso – volume: 25 start-page: 5849 year: 2017 ident: 6018_CR15 publication-title: Bioorg Med Chem doi: 10.1016/j.bmc.2017.09.023 contributor: fullname: P Damonte – volume: 9 start-page: 1956 year: 2010 ident: 6018_CR34 publication-title: Mol Cancer Ther doi: 10.1158/1535-7163.MCT-09-1012 contributor: fullname: H Hirai |
SSID | ssj0000330256 |
Score | 2.4382336 |
Snippet | Pancreatic cancer is a highly aggressive cancer, and is primarily treated with gemcitabine, with increasing resistance. SIRT6 as a member of sirtuin family... Abstract Pancreatic cancer is a highly aggressive cancer, and is primarily treated with gemcitabine, with increasing resistance. SIRT6 as a member of sirtuin... Abstract Pancreatic cancer is a highly aggressive cancer, and is primarily treated with gemcitabine, with increasing resistance. SIRT6 as a member of sirtuin... |
SourceID | doaj pubmedcentral proquest crossref pubmed |
SourceType | Open Website Open Access Repository Aggregation Database Index Database |
StartPage | 499 |
SubjectTerms | 1-Phosphatidylinositol 3-kinase Acetylation AKT protein Antitumor activity Antitumor agents Apoptosis Cancer therapies Cell Line, Tumor Cell proliferation Deacetylation Deoxycytidine - pharmacology Deoxycytidine - therapeutic use Diabetes mellitus DNA damage DNA repair Drug development Gemcitabine Humans Life span Neurodegenerative diseases Pancreatic cancer Pancreatic Neoplasms - pathology Phosphatidylinositol 3-Kinases - metabolism Pyrroles - pharmacology Pyrroles - therapeutic use Sirtuins - metabolism Therapeutic targets TOR protein Xenograft Model Antitumor Assays |
SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1La9wwEBYlUOil9F2naVGht2JirSVZPvYV0kJ7aBPITejlxtB4w9opbOiP7yfJWXZLoZfig40kG1kzo_kGj78h5BXzAK2sU2UllC25C21pjJQlt0FKo6x3iY7h8xd5fMo_nYmzrVJfMScs0wPnhTtsa2AC2bWGt4p7XHjECAEoiwuPlky2zcRWMJX2YITpcObzXzJVrQ5Hznj8X2cRixlUDKHTjidKhP1_Q5l_JktueZ-je-TuDBvpmzzd--RWGB6Q27mQ5Poh-fW-H11MxlzTZUcNvVyvYtpgiXMP59Rf9N5co4F6KNzPxPVNzUgH3PKDfvv49UTSfjjvLcx7RQFj6Rjz2qf-Go6NYr_I0NJRF3VkRacl_R4uXD8ZxNXhETk9-nDy7ric6yqUjrfNVNadlAsvvG24ZUAccPlWtsoJZVTjOW8QM0k4LRzOsgBQ12BwYKGJZHE4HpO9YTmEp4QGwY0ASjSmbrEV1CpAQk0wC-7azhtekNc3a6wvM32GTp-9a6WzRDSeqZNENCvI2yiGzchIfZ0aoBB6Vgj9L4UoyMGNEPVsj6OGE45EewjfCvJy0w1Lip9HzBCWV2mMBJoF6CzIkyzzzUxSoeAq3q12tGFnqrs9Q3-e2LoR71a1aPj-_3i5Z-TOIqkwjIsfkL1pdRWeAxVN9kUygN9i2gkI priority: 102 providerName: Directory of Open Access Journals – databaseName: AUTh Library subscriptions: ProQuest Central dbid: BENPR link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3da9UwFA9zQ_BF_LY6JYJvEm57m6bpkzjduAoOmRvsreSrW8G117YT7vCP95e09-oVkT60pGkber5-Jzk5h5DXiQVoTSrJ4kxqxo0rmFJCMK6dEEpqa0I6hs_HYnHGP51n5ztksd4L48Mq1zoxKGrbGj9HPoMa9anSAMBnSvtZADPM3i6_M18_yq-zTsU0bpG9ecL9gu3eweHxl5PNfEsMxx3mfdo3E6dy1nN0LBiMFvNJSeBMbdmmkML_X7jz7_DJP-zR0T1ydwKS9N1I-ftkxzUPyO2xtOTqIfn5oe6ND89c0baiii5XnQ8kZDjXMFf1VW3VDRqoBQv-CNm_qeppg0e-0a8fT04FrZvLWkPgOwpgS3sf6T7UNzB1FBpkBJuGGs81HR1aeuGuTD0oeNruETk7Ojx9v2BTpQVmeJEPLK2EmNvM6pzrBBgEIECLQppMKplbznN4UQJmDIfRiQPMy9HZJS736eNwPCa7Tdu4p4S6jKsMuFGptIBySKUTVZE7NeemqKziEXmz_sflckyoUYaF8FSWI0VKvLMMFCmTiBx4Mmx6-mTYoaHtLspJtsoiBWzEVxQvJLe4sHAjHYA4zyxaRET210QsJwnty9_8FJFXm9uQLb9gohrXXoc-AvgWMDQiT0aab0YSSgfH_mm5xQ1bQ92-09SXIX83POA4zXL-7P_jek7uzANzQpD4Ptkdumv3Agho0C8n5v4Ft5UGzg priority: 102 providerName: ProQuest – databaseName: Scholars Portal Open Access Journals dbid: M48 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwdV1Nb9QwEB2VIlAvFd-kFGQkbiiwSRzHOSDEV1WQygG6Um-WEzttpDYpSYrYih_Ps5NdsWhRDokcx4kybzxv5PEM0YvIgLRGlQxnqSxCXto81FqIkBdWCC0LU_p0DEdfxeGcfzlJT7ZoWe5o-oH9RtfO1ZOad-evfv1YvIXCvxm3jMvXPY-424oTuzoFswhe0Q26GfOEO8QfTXTfz8xw3mHip70zmx_dodu-KuxMxGumymf030RD_42m_Ms8Hdyh3YlXsncjEO7Slm3u0a2x0uTiPv3-WPeli9ZcsLZiml0uOhdXGOJcw3rVF7XR12hgBoj86ZOBM92zBo-cs--fvx0LVjdndQH97xh4Lutd4PtQX8PyMUwoI_csWelA1LGhZaf2oqwHDcfbPqD5wafjD4fhVHghLHmeDWFSCRGb1BQZLyJQEnCCQuSyTKWWmeE8g1MlYNVwlEVkwfoydLaRzVw2ORwPabtpG_uYmE25TkEjtU5yzBWJtKLKM6tjXuaV0Tygl8t_rC7H_BrKr4snUo3CURhTeeGoKKD3Tgyrni43tm9ou1M1qZrKE7BIvEXzXHKDCwOv0oKX89SgRQS0vxSiWuJNwUq7THzw7wJ6vroNVXPrJ7qx7ZXvI0B3wUoDejTKfPUlS8wEJNfQsPap63ea-syn84ZDPEvSjO_9d9AntBN7iEKl-D5tD92VfQouNBTPPMD_ABa0BIU priority: 102 providerName: Scholars Portal |
Title | Discovery of a pyrrole-pyridinimidazole derivative as novel SIRT6 inhibitor for sensitizing pancreatic cancer to gemcitabine |
URI | https://www.ncbi.nlm.nih.gov/pubmed/37542062 https://www.proquest.com/docview/2845977862/abstract/ https://search.proquest.com/docview/2846932009 https://pubmed.ncbi.nlm.nih.gov/PMC10403574 https://doaj.org/article/938516f9a4984d6f9d828e81d45d9846 |
Volume | 14 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3da9swED_ajo2-lH3PWxc02NtwE8eyLD-uXUs3SFe6FvJmZEluDY0TEneQ0j9-P8lxaMaehsA2-rCF7073O-l0IvocGYDWqJThIJFFyLXNQqWECHlhhVCyMNqHYxididMr_mOcjLdIdHthvNO-LqqD-nZyUFc33rdyNtH9zk-sfz46ggkxiJOU97dpO43jRza6H39hokORr3bIDGLZX_CIu706Q3eQwSCC2bRLz_zZrwMx3FBIPm7_v8Dm3z6Tj5TQyXPaW6FH9rXt5QvasvVLetqeJ7l8RQ_fqoV2PplLNi2ZYrPl3HkPhrhX0FHVpDLqHhnMgO9--5DfTC1YjSa37Nf3i0vBqvqmKiDlcwY0yxbOvb2p7qHfGIaNFmFqph2rzFkzZdd2oqtGwby2r-nq5Pjy6DRcHa8Qap6lTRiXQgxNYoqUFxGABzR_ITKpE6lkajhPYToJ6C4kXUQW2C5FZRvZ1MWMQ3pDO_W0tu-I2YSrBGBRqTjDiBBLK8ostWrIdVYaxQP60v3jfNZG0cj96ncs85Y4Od6Ze-LkUUCHjgzrmi4Cts-Yzq_zFR_kWQysiK8onklu8GBgO1qgb54Y5IiA9jsi5iuxXOTQxS7eHqy4gD6tiyFQbpVE1XZ65-sIgFpgz4DetjRf96TjmYDkBjdsdHWzBDzsg3Z3PPv-_5t-oN2h52FIFt-nnWZ-Zz8CEjVFD3IwTnv05PD47Pyi5ycWcB1x2XOzjj97XkL-AG8XECU |
link.rule.ids | 230,315,733,786,790,870,891,2115,12083,21416,24346,27957,27958,31754,31755,33779,33780,43345,43840,53827,53829,74102,74659 |
linkProvider | National Library of Medicine |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9QwELagCMEF8SyBAkbihqImG8d2TohXtYW2B9hKe7Mc22kj0WTZpEhb8eP57GQXFiGUQyLHSazM6xt7PEPIq9QCtKaVjJNcljEzroi15jxmpeNcy9KakI7h-IRPT9mneT4fJ9y6MaxyrRODorat8XPk-1CjPlUaAPibxffYV43yq6tjCY3r5AbLMuZD-sRcbOZYEjjrMOnjXpkkk_sdS5nftTPxJQ2SFA7Ulj0Kafv_hTX_Dpn8wwYd3CV3RvBI3w7UvkeuueY-uTmUk1w9ID8_1J3xIZkr2lZU08Vq6YMHY5xrmKj6orb6Cg3Ugu1-hIzfVHe0wSPf6NfDLzNO6-a8LiHkSwowSzsf3d7XVzBvFFpjAJiGGs8pS9q39MxdmLrX8K7dQ3J68HH2fhqP1RViwwrRx1nF-cTmthSsTIE7YPhLXkiTSy2FZUzAc-IwXThMmTpAO4HOLnXCp4zD8YjsNG3jHhPqcqZzYEWtswIKIZOOV4VwesJMUVnNIvJ6_Y_VYkiiocLidybVQBGFd6pAEZVG5J0nw6anT4AdGtrlmRrlSRUZoCK-olkhmcWFhevoAL5ZbtHCI7K3JqIapbJTv3koIi83tyFPfpFEN669DH04MC2gZ0R2B5pvRhLKBSf-abnFDVtD3b7T1OchZze83iTLBXvy_3G9ILems-MjdXR48vkpuT0JjApBYntkp19eumdAQH35PLD5L0xVBJs |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1bi9QwFA66ovgiXtfqqhF8kzLtNE3SJ1HXYdfLIroL8xbSJN0tuO047Qqz-OP9knZGR0T60JJLG3pu32lOzyHkRWoBWtNKxkkuy5gZV8Racx6z0nGuZWlNSMfw6YgfnLD383w-xj91Y1jlWicGRW1b47-RT6BGfao0APBJNYZFfN6fvVp8j30FKb_TOpbTuEquwUomvpqBmIvN95YEjjvM-_jfTJLJScdS5v_gmfryBkkKZ2rLNoUU_v_CnX-HT_5hj2a3ya0RSNLXA-XvkCuuuUuuD6UlV_fIz_26Mz48c0Xbimq6WC19IGGMcw1zVZ_XVl-igVqw4I-Q_ZvqjjaY8o1-PfxyzGndnNUlBH5JAWxp5yPd-_oSpo5Cgwxg01DjuWZJ-5aeunNT9xqetrtPTmbvjt8exGOlhdiwQvRxVnE-tbktBStTYBCAgJIX0uRSS2EZE_CiOMwYDlOmDjBPYLBLnfDp43A8IDtN27iHhLqc6Ry4UeusgHLIpONVIZyeMlNUVrOIvFy_Y7UYEmqosBGeSTVQROGeKlBEpRF548mwGemTYYeGdnmqRtlSRQbYiKdoVkhmcWHhRjoAcZZbtPCI7K2JqEYJ7dRvforI8003ZMtvmOjGtRdhDAe-BQyNyO5A881KQungxM-WW9ywtdTtnqY-C_m74QEnWS7Yo_-v6xm5AQ5XHw-PPjwmN6eBTyFTbI_s9MsL9wRgqC-fBi7_BWdWCMc |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Discovery+of+a+pyrrole-pyridinimidazole+derivative+as+novel+SIRT6+inhibitor+for+sensitizing+pancreatic+cancer+to+gemcitabine&rft.jtitle=Cell+death+%26+disease&rft.au=Song%2C+Nannan&rft.au=Guan%2C+Xian&rft.au=Zhang%2C+Siqi&rft.au=Wang%2C+Yanqing&rft.date=2023-08-04&rft.eissn=2041-4889&rft.volume=14&rft.issue=8&rft.spage=499&rft_id=info:doi/10.1038%2Fs41419-023-06018-1&rft_id=info%3Apmid%2F37542062&rft.externalDocID=37542062 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2041-4889&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2041-4889&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2041-4889&client=summon |